|
43 Companies |
|
40 Products |
|
40 Products |
|
30 Mechanisms of Action |
|
1 Trial |
|
293 News |
|
| «1234567 |
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial, Combination therapy: Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Nov 15, 2011
P3, N=200, Recruiting, Sponsor: Ming Hou
- |||| Trial completion: Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC) (clinicaltrials.gov) - Nov 15, 2011
P2, N=122, Completed, Sponsor: Taisho Pharmaceutical R&D Inc.
Active, not recruiting --> Completed
- |||| Doptelet (avatrombopag) / SOBI
Trial completion: Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 13, 2011
P2, N=64, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open: Incritop: Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=199, Recruiting, Sponsor: Ming Hou
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P2 trial: Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Oct 20, 2011
P2, N=30, Not yet recruiting, Sponsor: mamdouh abdulmaksoud abdulrhman
- Trial termination: Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions (clinicaltrials.gov) - Oct 2, 2011
P1/2, N=50, Terminated, Sponsor: University of Michigan
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Slow enrollment
- |||||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
New P3 trial: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Sep 28, 2011
P3, N=60, Recruiting, Sponsor: Amgen
- | Benlysta (belimumab) / GSK
New P2 trial: A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. (clinicaltrials.gov) - Sep 22, 2011
P2, N=48, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||| Promacta (eltrombopag) / Novartis
Clinical: Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=280, Completed, Sponsor: GlaxoSmithKline
- ||| Doptelet (avatrombopag) / SOBI
New P3 trial: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) - Sep 20, 2011
P3, N=49, Completed, Sponsor: Eisai Inc.
- | Doptelet (avatrombopag) / SOBI
New P1 trial: Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. (clinicaltrials.gov) - Sep 18, 2011
P1, N=36, Completed, Sponsor: Eisai Inc.
- | New P1/2 trial: Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates (clinicaltrials.gov) - Sep 13, 2011
P1/2, N=616, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
- Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
New P3 trial: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) - Sep 12, 2011
P3, N=24, Terminated, Sponsor: Eisai Inc.
- |||||||||| New P3 trial: Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis (clinicaltrials.gov) - Sep 11, 2011
P3, N=290, Completed, Sponsor: Novartis
- New P3 trial: PLEX-RCT: The Plasma Large-Volume Exchange RCT (clinicaltrials.gov) - Sep 11, 2011
P3, N=0, Withdrawn, Sponsor: London Health Sciences Centre
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Trial completion: A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Sep 5, 2011
P3, N=35, Completed, Sponsor: Bio Products Laboratory
Active, not recruiting --> Terminated; Slow enrollment Active, not recruiting --> Completed